FGF21: a promising therapeutic agent for alcoholic cardiomyopathy?.
J Pathol
; 254(3): 213-215, 2021 07.
Article
in English
| MEDLINE | ID: covidwho-1272229
ABSTRACT
The metabolic regulator fibroblast growth factor 21 (FGF21) has been reported as a cardioprotective factor regulating cardiac remodeling in several cardiac diseases. In a recent issue of The Journal of Pathology, Ferrer-Curriu, Guitart-Mampel et al investigated FGF21 in alcoholic cardiomyopathy (ACM). They showed that FGF21 deficiency aggravates alcohol-induced cardiac damage and dysfunction by exacerbating mitochondrial alterations, oxidative stress, and lipid metabolic dysregulation, suggesting FGF21 as a promising therapeutic agent in ACM. Paradoxically, FGF21 cardiac and circulating levels correlate with cardiac damage and oxidative stress in patients with ACM, pointing to FGF21 as a potential biomarker of alcohol-induced cardiac damage. Further studies are needed to address when FGF21 can be used as a diagnostic biomarker and when it can be used as a therapeutic agent to treat ACM. © 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cardiomyopathy, Alcoholic
Limits:
Humans
Country/Region as subject:
Europa
Language:
English
Journal:
J Pathol
Year:
2021
Document Type:
Article
Affiliation country:
Path.5654
Similar
MEDLINE
...
LILACS
LIS